ArticleWorld journal of surgical oncology2025
Oncologic outcomes of surgical delay by interval and tumor size in T1b-T2aN0M0 renal cell carcinoma.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Delayed diagnostic imaging but stable treatment initiation for kidney cancer during the COVID-19 pandemic: a Hungarian cohort study.Pathology oncology research : POR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSurgical delay is often unavoidable in the management of localized renal cell carcinoma (RCC), but the safe duration for postponing surgery remains unclear, particularly for RCC of varying sizes.
methodsPatients diagnosed with T1a-T2bN0N0 RCC between 2000 and 2022 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable Cox proportional hazards models were used to assess the impact of surgical delays of more than 1, more than 2, and more than 3 months on cancer-specific survival (CSS). Subgroup analyses were performed according to tumor size categories (4.0-5.9 cm, 6.0-7.9 cm, and 8.0-10.0 cm) at each surgical delay interval.
resultsA total of 39,242 patients were included, with a median follow-up time of 80 months (Interquartile range [IQR], 37-138 months). Surgical delays of more than 1 month did not worsen CSS in patients with tumors 4.0-5.9 cm (adjusted HR = 1.05, 95% CI, 0.93-1.18, p = 0.412), 6.0-7.9 cm (adjusted HR = 1.04, 95% CI, 0.92-1.17, p = 0.512), or 8.0-10.0 cm (adjusted HR = 1.07, 95% CI 0.93-1.23, p = 0.376). Delays of more than 2 months showed no significant CSS difference in tumors 4.0-5.9 cm (adjusted HR = 1.06, 95% CI 0.91-1.21, p = 0.496) or 6.0-7.9 cm (adjusted HR = 1.06, 95% CI 0.90-1.25, p = 0.463), but CSS worsened in tumors sized 8.0-10.0 cm (adjusted HR = 1.29, 95% CI 1.06-1.57, p = 0.012). For delays of more than 3 months, CSS was unaffected in tumors 4.0-5.9 cm (adjusted HR = 1.11, 95% CI 0.92-1.31, p = 0.508), but was worse in tumors 6.0-7.9 cm (adjusted HR = 1.28, 95% CI 1.03-1.66, p = 0.021) and 8.0-10.0 cm (adjusted HR = 1.29, 95% CI 1.09-1.52, p = 0.003).
conclusionSurgical delay was not associated with worse CSS for RCC measuring 4.0-5.9 cm within 3 months. For tumors measuring 6.0-7.9 cm and 8.0-10.0 cm, delays of more than 3 months and more than 2 months, respectively, appeared to be linked with worse CSS. However, due to the retrospective nature and potential residual confounding of this study, these findings should be interpreted with caution. Prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.